Healthspan & Quality Of Life Annual Report

Overview

The report describes iX Biopharma's FY2017 progress in drug and nutraceutical development, including the launch of WafeRest in Singapore, the launch of BnoX in Australia and recruitment for the KET010 Phase 2 Wafermine study. It also reports the incorporation of Entity Health and development of a broader nutraceutical pipeline. The sustainability statement covers environmental, people, product and governance priorities, including transportation-emissions reduction, equal-opportunity hiring and product-safety monitoring. Group revenue was 6,381 $'000 and total loss was 7,390 $'000.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2017
Period: Ends 30 June 2017
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services